SRT 2104
Based on 25 publication(s) in Google Scholar
SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD+ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.27%
- CAS No.: 1093403-33-8
- Formule: C26H24N6O2S2
- Masse moléculaire:516.64
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-15452
SelisistatSirT1/Sir2 Inhibitor -
HY-10532
SRT 1720SIRT1 Activator -
HY-16561
ResveratrolPolyphenolic Phytoalexin -
HY-124037
SRT 1460Sirtuin Activator -
HY-100591
SirReal2Sirt2 Inhibitor -
HY-16691
AK-7Sirtuin Inhibitor -
HY-19759
SRT 2183SIRT1 Activator -
HY-123033A
Nicotinamide riboside chlorideEndogenous Metabolite -
HY-108331
3-TYPSIRT3 Inhibitor -
HY-100578
AGK2SIRT2 Inhibitor -
HY-15452R
Selisistat (Standard)SirT1/Sir2 Inhibitor -
HY-13515
SirtinolSirtuin Inhibitor
Publications Citing Use of MedChemExpress (MCE) SRT 2104
More- J Clin Invest. 2026 Feb 26:e200062. [Abstract]
- Adv Sci (Weinh). 2025 Sep 26:e10103. [Abstract]
- Neural Regen Res. 2021 Dec;16(12):2465-2474. [Abstract]
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- Ecotoxicol Environ Saf. 2024 Nov 15:287:117253. [Abstract]
- Biochem Pharmacol. 2026 Jun 25;251(Pt 2):118200. [Abstract]
- Pak Vet J. 2026 Feb 14.46(2):460-467.
- J Endocrinol. 2018 Apr;237(1):1-14. [Abstract]
- Int J Mol Sci. 2023 Jul 6;24(13):11135. [Abstract]
- Int J Mol Sci. 2023 Apr 9;24(8):6968. [Abstract]
- Biomolecules. 2022 Mar 9;12(3):422. [Abstract]
- J Mol Med (Berl). 2018 Sep;96(9):939-949. [Abstract]
- Sci Rep. 2026 Mar 17;16(1):13946. [Abstract]
- Sci Rep. 2025 Oct 29;15(1):37837. [Abstract]
- Brain Res Bull. 2023 Oct 15:203:110780. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1272-1281. [Abstract]
- J Funct Foods. 2024 Dec.
- COPD. 2020 Aug;17(4):444-451. [Abstract]
- Cartilage. 2021 Dec;13(2_suppl):1356S-1366S. [Abstract]
- J Food Biochem. 2026 May 25;2026(1):3782560.
- Neurosci Lett. 2021 Sep 14:761:136112. [Abstract]
- Biomed Pharmacother. 2025 Sep:190:118391. [Abstract]
- Res Sq. 2025 May 15.
- bioRxiv. 2025 Feb 1:2025.01.30.635746. [Abstract]
- Patent. US20180263995A1.
Customer Validation & Images
-
IP
-
WB
-
Cell Proliferation/Viability Assay
-
WB
-
RT-PCR
Activité biologique
Description
IC50 & Target
[1]|
SIRT1 |
In Vivo
SRT 2104 (100 mg/kg/day, supplemented in diet for 24 weeks) decreases testicular oxidative stress, activation of apoptotic signaling, and ER stress in diabetic mice[2].
SRT 2104 (0.5% in diet; p.o.; for 18 weeks) improves motor function and increases survival in N171-82Q HD mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (8-week-old)[2]
-
Dosage:100 mg/kg/day
-
Administration:Supplemented in diet for 24 weeks
-
Result:Enhanced SIRT1 protein without evelating Sirt1 mRNA level. Attenuated diabetes mellitus (DM)-induced oxidative stress, apoptotic signaling, and ER stress.
-
Animal Model:WT and N171-82Q HD mice (6 weeks old)[3]
-
Dosage:0.5%
-
Administration:0.5% SRT 2104 containing diet for 6, 12, 18 weeks
-
Result:Ameliorated motor deficits and increased survival in N171-82Q HD mice.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1093403-33-8
-
Appearance Solid
-
Masse moléculaire 516.64
-
Formule C26H24N6O2S2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(C)N=C(C2=CC=CN=C2)S1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCOCC6)=N4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (25)
-
Journal Impact Factor
-
Most Recent
-
J Clin Invest
CD38 expression by neonatal human naive CD4+ T cells shapes their distinct metabolic and tolerogenic properties. [Abstract]2026 Feb 26:e200062. PMID: 41746743 -
Adv Sci (Weinh)
2025 Sep 26:e10103. PMID: 40999873
SRT 2104 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep 26:e10103. [Abstract]
ATDC5 cells were treated with different concentrations of SRT2104 (SRT; 0, 0.5, 1 μM), a specific Sirt1 activator, for 48 h, reduced the acetylation of Piezo1.
SRT 2104 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep 26:e10103. [Abstract]
After SRT2104 (SRT; 0, 0.25, 0.5, 1, 2 μM) intervention in ATDC5 cells for 48 h, western blotting was used to detect the expression of Piezo1 protein in the cells.
-
Neural Regen Res
Hippocampal insulin resistance and the Sirtuin 1 signaling pathway in diabetes-induced cognitive dysfunction. [Abstract]2021 Dec;16(12):2465-2474. PMID: 33907035
SRT 2104 purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2021 Dec;16(12):2465-2474. [Abstract]
SRT2104 (10 μM) was intracerebroventricularly injected into six diabetic model rats for 16 days, increasing SIRT1, TORC1, p-CREB, and BDNF levels in the hippocampus.
SRT 2104 purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2021 Dec;16(12):2465-2474. [Abstract]
SRT2104 (10 μM) was intracerebroventricularly injected into six diabetic model rats for 16 days, significantly increasing the dendritic lengths and spine densities in the hippocampus of diabetic model rats.
-
-
Ecotoxicol Environ Saf
Acetylation of FOXO1 is involved in cadmium-induced rat kidney injury via mediating autophagosome-lysosome fusion blockade and autophagy inhibition. [Abstract]2024 Nov 15:287:117253. PMID: 39536554 -
Biochem Pharmacol
Dapagliflozin ameliorates diabetic kidney disease by inhibiting oxidative stress and AIM2-dependent pyroptosis via SIRT1 activation. [Abstract]2026 Jun 25;251(Pt 2):118200. PMID: 42349619 -
-
J Endocrinol
SRT2104 attenuates diabetes-induced aortic endothelial dysfunction via inhibition of P53. [Abstract]2018 Apr;237(1):1-14. PMID: 29371235 -
Int J Mol Sci
The Impact of SRT2104 on Skeletal Muscle Mitochondrial Function, Redox Biology, and Loss of Muscle Mass in Hindlimb Unloaded Rats. [Abstract]2023 Jul 6;24(13):11135. PMID: 37446313 -
Int J Mol Sci
Downregulation of Sirtuin 1 Does Not Account for the Impaired Long-Term Potentiation in the Prefrontal Cortex of Female APPswe/PS1dE9 Mice Modelling Alzheimer's Disease. [Abstract]2023 Apr 9;24(8):6968. PMID: 37108131 -
Biomolecules
2022 Mar 9;12(3):422. PMID: 35327614 -
J Mol Med (Berl)
MicroRNA-34a targets sirtuin 1 and leads to diabetes-induced testicular apoptotic cell death. [Abstract]2018 Sep;96(9):939-949. PMID: 30030567
SRT 2104 purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2018 Sep;96(9):939-949. [Abstract]
To test the effect of miR-34a inhibition and SIRT1 activation on the expression of miR-34a and Sirt1, the diabetic mice are treated with NC-I, miR-34a-I or SRT2104. Sirt1 mRNA levels are determined by qPCR.
-
Sci Rep
SIRT1 induces FOXO1/autophagy/NCOA4-induced ferroptosis and accelerates the progression of cerebral infarction by inhibiting the E2F1/NOTCH-1/YAP signaling pathway. [Abstract]2026 Mar 17;16(1):13946. PMID: 41844756 -
Sci Rep
Luteoloside alleviates bleomycin-induced pulmonary fibrosis in mice via SIRT1-mediated protective effect against alveolar epithelial cell senescence. [Abstract]2025 Oct 29;15(1):37837. PMID: 41162593 -
Brain Res Bull
Arc regulates brain damage and neuroinflammation via Sirt1 signaling following subarachnoid hemorrhage. [Abstract]2023 Oct 15:203:110780. PMID: 37820952 -
Biochim Biophys Acta Mol Cell Res
2019 Aug;1866(8):1272-1281. PMID: 30959066 -
-
COPD
Therapeutic Effects of SRT2104 on Lung Injury in Rats with Emphysema via Reduction of Type II Alveolar Epithelial Cell Senescence. [Abstract]2020 Aug;17(4):444-451. PMID: 32722945 -
Cartilage
Inhibition of Knee Osteoarthritis Progression in Mice by Administering SRT2014, an Activator of Silent Information Regulator 2 Ortholog 1. [Abstract]2021 Dec;13(2_suppl):1356S-1366S. PMID: 31989845
SRT 2104 purchased from MedChemExpress. Usage Cited in: Cartilage. 2021 Dec;13(2_suppl):1356S-1366S. [Abstract]
Safranin O-fast green staining of the medial knee joint at 4, 8, 12, and 16 weeks postsurgery. Scale bar = 100 μm.
-
-
Neurosci Lett
Ameliorative effect of SIRT1 in postpartum depression mediated by upregulation of the glucocorticoid receptor. [Abstract]2021 Sep 14:761:136112. PMID: 34265417 -
Biomed Pharmacother
Vitamin D and SIRT1 activator SRT2104 cooperate in antiproliferative activity in lung cancer through ferroptosis induction. [Abstract]2025 Sep:190:118391. PMID: 40768932
SRT 2104 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep:190:118391. [Abstract]
Cells were treated with SRT2104 at the concentration of 5 and 12.5 µM for 96 h.
SRT 2104 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep:190:118391. [Abstract]
Lung cancer cell lines were treated with calcitriol (10 nM for EGFR mutant cells and HSAEC or 100 nM for other cell lines) and SRT2104 (5 µM) for 72 h. Representative blots of VDR, CYP24 A1 and SIRT1.
SRT 2104 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep:190:118391. [Abstract]
Lung cancer cell lines were treated with calcitriol (10 nM for EGFR mutant cells and HSAEC or 100 nM for other cell lines) and SRT2104 (5 µM) for 72 h. Relative CYP24 A1 mRNA expression determined by RT-qPCR.
-
-
bioRxiv
2025 Feb 1:2025.01.30.635746. PMID: 39975205 -
Solvant et solubilité
In Vitro:
DMSO : 5 mg/mL (9.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.5 mg/mL (0.97 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hoffmann E, et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. [Content Brief]
[2]. Jiao D, et al. MicroRNA-34a targets sirtuin 1 and leads to diabetes-induced testicular apoptotic cell death. J Mol Med (Berl). 2018 Sep;96(9):939-949. [Content Brief]
[3]. Jiang M, et al. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9356 mL | 9.6779 mL | 19.3558 mL | 48.3896 mL |
| 5 mM | 0.3871 mL | 1.9356 mL | 3.8712 mL | 9.6779 mL |
SRT 2104 Related Classifications
HY-15262 Related Classifications
Powered by Bioz